Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer

被引：53
|
作者：
Liu, Xiaochen [1 ,2 ,5 ]
Wang, Dangge [1 ,2 ,3 ]
Zhang, Pengcheng [1 ,2 ,3 ]
Li, Yaping [1 ,2 ,4 ]
机构：
[1] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China
[3] Yantai Inst Mat Med, Yantai Key Lab Nanomed & Adv Preparat, Yantai 264000, Shandong, Peoples R China
[4] Yantai Univ, Sch Pharm, Yantai 264005, Shandong, Peoples R China
[5] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
来源：
NANO TODAY | 2019年 / 29卷
基金：
中国国家自然科学基金;
关键词：
Nanosized drug delivery systems; Nanoparticles; Biomimetic vehicles; PD-1/PD-L1; blockade; Cancer immunotherapy; IMMUNE-CHECKPOINT BLOCKADE; IMMUNOGENIC CELL-DEATH; ANTITUMOR IMMUNITY; LIPID NANOPARTICLES; COMBINATION THERAPY; LUNG-CANCER; TUMOR; ANTI-PD-1; PEMBROLIZUMAB; RADIOTHERAPY;
D O I：
10.1016/j.nantod.2019.100801
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Checkpoint blockade immunotherapy revolutionizes the field of cancer therapy, among which anti-programmed cell death (anti-PD) therapy is the most successful one in clinic. Despite the tremendous advancement, anti-PD therapy is still limited by barriers such as low response rate and immune related adverse effects (AEs), which are mainly resulted from poor intratumoral infiltration of cytotoxic T lymphocytes and off-tumor distribution of the anti-PD drugs. To address these issues, nanosized drug delivery systems (NDDS) have been fabricated to realize synergistic application with anti-PD drugs for anti-tumor immunity priming or enable targeting delivery of anti-PD drugs with versatile chemical properties. In this review, we summarize the major barriers for successful anti-PD therapy, highlight current advances in NDDS with improved anti-PD therapeutic benefits, and discussed the possible directions of the field. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页数：19
相关论文
共 50 条
  • [31] Recent advances in colon drug delivery systems
    Arevalo-Perez, Roberto
    Maderuelo, Cristina
    Lanao, Jose M.
    JOURNAL OF CONTROLLED RELEASE, 2020, 327 : 703 - 724
  • [32] Recent advances in polymeric drug delivery systems
    Yong Kiel Sung
    Sung Wan Kim
    Biomaterials Research, 24
  • [33] Recent Advances in Prodrugs as Drug Delivery Systems
    Lin, Congrong
    Sunkara, Gangadhar
    Cannon, John B.
    Ranade, Vasant
    AMERICAN JOURNAL OF THERAPEUTICS, 2012, 19 (01) : 33 - 43
  • [34] Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy
    Zhou, Lei
    Zhang, Pengcheng
    Wang, Hao
    Wang, Dangge
    Li, Yaping
    ACCOUNTS OF CHEMICAL RESEARCH, 2020, 53 (09) : 1761 - 1772
  • [35] Recent advances of morphology adaptive nanomaterials for anti-cancer drug delivery
    Dongbing Cheng
    Zengying Qiao
    Lixue Xuan
    Hao Wang
    Progress in Natural Science:Materials International, 2020, 30 (05) : 555 - 566
  • [36] Recent advances of morphology adaptive nanomaterials for anti-cancer drug delivery
    Cheng, Dong-Bing
    Qiao, Zeng-Ying
    Xuan, Lixue
    Wang, Hao
    PROGRESS IN NATURAL SCIENCE-MATERIALS INTERNATIONAL, 2020, 30 (05) : 555 - 566
  • [37] Overcoming key biological barriers to cancer drug delivery and efficacy
    Kim, Susy M.
    Faix, Peggy H.
    Schnitzer, Jan E.
    JOURNAL OF CONTROLLED RELEASE, 2017, 267 : 15 - 30
  • [38] Advances in nanomedicine for retinal drug delivery: overcoming barriers and enhancing therapeutic outcomes
    Panda, Pratikeswar
    Mohanty, Shreyashree
    Gouda, Sangita Ranee
    Mohapatra, Rajaram
    JOURNAL OF DRUG TARGETING, 2024,
  • [39] Recent advances in the field of anti-cancer immunotherapy
    Neves, Henrique
    Kwok, Hang Fai
    BBA CLINICAL, 2015, 3 : 280 - 288
  • [40] Recent advances in clinical anti-cancer immunotherapy
    Juretic, Antonio
    PERIODICUM BIOLOGORUM, 2014, 116 (04) : 365 - 370
12345